A US government agency has hit back at a plan by Johnson & Johnson to change the way it pays discounts on drugs to hospitals participating in the 340B programme for healthcare systems s
Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances nex
Johnson & Johnson’s blockbuster immunology drug Stelara is facing its first approved biosimilar in Europe, which is due to launch after the drug loses EU patent protec
A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent
AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S
